Kurser indlæses...

Prognose

Analytikernes gennemsnitlige kursmål er 2,72 € (+28.145,07 %). Medianen er 2,72 € (+28.145,07 %).

Køb
  2
Behold
  1
Sælg
  0

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Inotiv files for Chapter 11 and plans debt reduction

    Inotiv has filed a Chapter 11 petition with the US Bankruptcy Court for the Southern District of Texas and agreed to a pre‑negotiated restructuring plan with senior secured creditors and an ad hoc group of noteholders. The aim is to reduce liabilities of about $488 million by roughly $326 million; the company secured $25 million of DIP financing in addition to a previously provided $40 million bridge loan (a total of $65 million). Inotiv intends to continue operations, pay suppliers and wages in the ordinary course, and expects an expedited conclusion of the Chapter 11 proceedings. » Mere på de.investing.com


  • Inotiv: lenders suspend minimum liquidity requirement for April

    Inotiv’s lenders have agreed to waive the minimum liquidity covenant for the test dates on 3 and 10 April 2026. The exemption applies only to the minimum liquidity clause; other loan terms remain unchanged. Inotiv is under significant financial strain with $476m in total debt, a market capitalization of $8.92m and a current ratio of 0.3. The company also missed its Q1 2026 results and reported a cybersecurity incident discovered in August 2025 that may have compromised personal data. » Mere på de.investing.com


  • Cyberattack at Inotiv compromises sensitive employee data

    Inotiv reported a cyberattack in which unauthorized access to systems occurred between August 5 and August 8, 2025, and potentially exposed names, Social Security numbers, driver’s license numbers, financial and medical information of current and former employees and their dependents. The incident was discovered on August 8 and reported to the SEC on August 18; the company has launched investigations, engaged external security experts and authorities, and notified affected individuals. Inotiv is offering credit monitoring, has seen no misuse so far but urges increased vigilance; the stock is trading near its 52-week low and 2026 is still expected to show a negative EPS of -$0.26. » Mere på de.investing.com


  • Inotiv receives preliminary court approval for $2.49 million derivatives settlement

    The U.S. District Court for the Northern District of Indiana granted Inotiv preliminary approval of a proposed settlement in two consolidated derivative suits, which provides for the implementation of certain corporate governance measures and a payment of $2.49 million. The payment is to be funded from insurance proceeds; attorneys’ fees of up to $2.25 million are also expected to be covered by insurance. A hearing for final approval is scheduled for March 18, 2026. » Mere på de.investing.com


  • Inotiv enters partnership with VUGENE to accelerate AI-driven drug discovery

    Inotiv announced a strategic collaboration with VUGENE to integrate VUGENE’s cloud-based multi-omics bioinformatics and AI platform into its Discovery & Translational Sciences division, aiming to improve analysis of complex biological data for drug discovery. The cooperation is intended to enhance early-stage predictions of efficacy and safety and to give VUGENE the opportunity to expand its technologies in research settings. Despite significant financial strain at Inotiv (sharp share decline, current ratio 0.35, debt-to-capital 0.94), the company beat Q4 2025 expectations with earnings of -$0.25 per share (expected -$0.33) and revenue of $138.1 million (expected $132.54 million). » Mere på de.investing.com

I 2001 har Inotiv allerede udloddet 0,0691 € i udbytte. Den seneste udlodning fandt sted i juni 2001.

Virksomhedstal

I det seneste kvartal havde Inotiv en omsætning på 101,64 mio. € og et nettoresultat på -28,05 mio. €
(EUR) marts 2026
YoY
Omsætning 101,64 mio. -
Bruttofortjeneste 9,13 mio. -
Nettoresultat -28,05 mio. -
EBITDA -1,98 mio. -

Fundamentale data

Nøgletal Værdi
Markedsværdi
2,53 mio. €
Antal aktier
34,89 mio.
Højeste/laveste i 52 uger
2,21 € - 0,0151 €
Udbytte Nej
Beta
4,08
P/E (PE Ratio)
0,00
PEG (PEG Ratio)
0,00
K/I (PB Ratio)
0,00
P/S (PS Ratio)
0,00

Virksomhedsprofil

Inotiv, Inc. leverer lægemiddelopdagelses- og udviklingsydelser til farmaceutiske, kemiske og medicinske udstyrsindustrier; og sælger analyseinstrumenter til lægemiddeludviklings- og kontraktforskningsindustrierne. Virksomheden opererer gennem to segmenter, Contract Research Services og Research Products. Segmentet Contract Research Services tilbyder screening og farmakologisk testning, non-klinisk sikkerhedstestning, formuleringsudvikling, lovgivningsmæssig compliance og kvalitetskontroltestydelser. Dette segment leverer udvikling og validering af analysemetoder; lægemiddelmetabolisme-, bioanalyse- og farmakokinetiktestning til at identificere og måle koncentrationer af lægemidler og metabolitter i komplekse biologiske matricer; in vivo-prøvetagningsydelser til kontinuerlig overvågning af kemiske ændringer i levende organismer; stabilitetstestning for at sikre integriteten af forskellige opløsninger, der anvendes i non-kliniske og kliniske undersøgelser, samt analyser efter undersøgelser; non-kliniske toksikologi- og patologiydelser; og klimastyrede arkiveringsydelser til kunders data og prøver. Segmentet Research Products designer, udvikler, fremstiller og markedsfører in vivo-prøvetagningssystemer og tilbehør, herunder engangsartikler, træning og systemkvalificering; overvågningsværktøjer til fysiologi; platforme til væskekromatografi- og elektrokemiinstrumenter; analyseprodukter bestående af væskekromatografiske og elektrokemiske instrumenter med tilhørende tilbehør; og in vivo-prøvetagningsprodukter bestående af Culex-familien af automatiserede in vivo-prøvetagnings- og doseringsinstrumenter. Virksomheden opererer i USA, resten af Nordamerika, Stillehavsranden, Europa og internationalt. Den har en aftale med BioVaxys om at gennemføre præklinske toksicitetsundersøgelser for sit Covid-T-immundiagnostiske program. Virksomheden var tidligere kendt som Bioanalytical Systems, Inc. og ændrede navn til Inotiv, Inc. i marts 2021. Inotiv, Inc. blev grundlagt i 1974 og har hovedkontor i West Lafayette, Indiana.

Navn
Inotiv
CEO
Robert W. Leasure
Hjemsted West Lafayette, in
USA
Websted
Sektor
Industrivirksomheder
Branche
Luft- og rumfart samt forsvar
Børsnotering
25.11.1997
Medarbejdere 2.027

Tickersymboler

Børs Symbol
NASDAQ
NOTV
Frankfurt
BS50.F
Düsseldorf
BS50.DU
München
BS50.MU
🍪

Parqet  bruger cookies. Læs mere